📣 VC round data is live. Check it out!

Bioretec Valuation Multiples

Discover revenue and EBITDA valuation multiples for Bioretec and similar public comparables like aap Implantate, Acarix, BrainCool, Carclo and more.

Bioretec Overview

About Bioretec

Bioretec Ltd is a medical device company focusing on the development of safe, and reliable bioabsorbable and bioresorbable implants for pediatric and adult orthopedics. The company's products are used world wide and continue to further develop materials and products for high-load-bearing clinical applications. Some of its brands include RemeOs, Activa IM-N, ActivaPi, and ActivaScrew.


Founded

2003

HQ

Finland

Employees

47

Financials (LTM)

Revenue: $5M
EBITDA: ($9M)

EV

$29M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Bioretec Financials

Bioretec reported last 12-month revenue of $5M and negative EBITDA of ($9M).

In the same LTM period, Bioretec generated ($10M) in gross profit, ($9M) in EBITDA losses, and had net loss of ($10M).

Revenue (LTM)


Bioretec P&L

In the most recent fiscal year, Bioretec reported revenue of $4M and EBITDA of ($10M).

Bioretec is unprofitable as of last fiscal year, with gross margin of 65%, EBITDA margin of (233%), and net margin of (264%).

See analyst estimates for Bioretec
LTMLast FY202320242025202620272028
Revenue$5M$4M$5M$5M$4M
Gross Profit($10M)$3M$3M$4M$3M
Gross Margin(191%)65%70%71%66%
EBITDA($9M)($10M)($3M)($4M)($10M)
EBITDA Margin(182%)(233%)(70%)(85%)(237%)
EBIT Margin(189%)(242%)(78%)(92%)(247%)
Net Profit($10M)($11M)($4M)($5M)($11M)
Net Margin(210%)(264%)(97%)(102%)(269%)

Financial data powered by Morningstar, Inc.

Bioretec Stock Performance

Bioretec has current market cap of $33M, and enterprise value of $29M.

Market Cap Evolution


Bioretec's stock price is $0.02.

Bioretec share price decreased by 5.5% in the last 30 days, and by 98.8% in the last year.

Bioretec has an EPS (earnings per share) of $-0.01.

See more trading valuation data for Bioretec
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$29M$33M-2.8%-5.5%-65.1%-98.8%$-0.01

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Bioretec Valuation Multiples

Bioretec trades at 5.8x EV/Revenue multiple, and (3.2x) EV/EBITDA.

See NTM and 2027E valuation multiples for Bioretec

EV / Revenue (LTM)


Bioretec Financial Valuation Multiples

As of June 4, 2026, Bioretec has market cap of $33M and EV of $29M.

Bioretec has a P/E ratio of (3.2x).

LTMLast FY202320242025202620272028
EV/Revenue5.8x7.0x6.4x5.5x7.1x
EV/EBITDA(3.2x)(3.0x)(9.2x)(6.5x)(3.0x)
EV/EBIT(3.1x)(2.9x)(8.2x)(6.0x)(2.9x)
EV/Gross Profit(3.0x)10.8x9.2x7.8x10.8x
P/E(3.2x)(3.0x)(7.6x)(6.2x)(3.0x)
EV/FCF(3.7x)(2.4x)(7.0x)(4.3x)(2.4x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Bioretec Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Bioretec Margins & Growth Rates

Bioretec grew revenue by 47% but EBITDA decreased by 20% in the last fiscal year.

In the most recent fiscal year, Bioretec reported gross margin of 65%, EBITDA margin of (233%), and net margin of (264%).

See estimated margins and future growth rates for Bioretec

Bioretec Margins

Last FY202420252026202720282029
Gross Margin65%71%66%(135%)
EBITDA Margin(233%)(85%)(237%)(127%)
EBIT Margin(242%)(92%)(247%)(134%)
Net Margin(264%)(102%)(269%)(154%)
FCF Margin(288%)(128%)(294%)(30%)

Bioretec Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth47%16%(22%)50%
Gross Profit Growth(408%)18%(28%)(408%)
EBITDA Growth(20%)42%116%(20%)
EBIT Growth(18%)39%107%(18%)
Net Profit Growth(14%)22%106%(14%)
FCF Growth(85%)62%77%(85%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Bioretec Operational KPIs

Bioretec's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.3M for the same period.

Bioretec's Rule of 40 is (78%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Bioretec's Rule of X is (3%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Bioretec
LTMLast FY202320242025202620272028
Rule of 40(131%)(78%)---
Bessemer Rule of X(54%)(3%)---
Revenue per Employee-$0.1M---
Opex per Employee-$0.3M---
Opex to Revenue-307%148%163%312%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Bioretec Competitors

Bioretec competitors include aap Implantate, Acarix, BrainCool, Carclo, Vivos, Ortoma, NeuroOne Medical, CytoSorbents, Implanet and Diagnostic Medical Systems.

Most Bioretec public comparables operate across Medical Devices, HealthTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
aap Implantate2.3x-(42.9x)-
Acarix35.3x21.8x(6.1x)(7.2x)
BrainCool6.6x6.4x(7.9x)(9.2x)
Carclo0.4x0.4x3.0x2.7x
Vivos----
Ortoma4.5x4.4x(69.8x)(23.1x)
NeuroOne Medical3.1x2.7x(9.4x)-
CytoSorbents1.5x1.4x(12.5x)-

This data is available for Pro users. Sign up to see all Bioretec competitors and their valuation data.

Start Free Trial

Bioretec VC Funding History

Before going public, Bioretec raised $9M in total equity funding, across 1 round.


Bioretec Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Jun-21Series ASpringvest$9M-Bioretec completed a EUR 7.2 million equity funding round on 23 June 2021 in cooperation with Springvest. The company develops medical devices, focusing on orthopedic implants using bioengineered LactiFix® polymer. For FY 2021, Bioretec reported net sales of EUR 2,003 thousand. In 2022, net sales grew to EUR 2,942 thousand, with 39% from Europe and increased demand in Asia driving 46.9% year-on-year growth. EBITDA for 2022 was EUR -2,112 thousand, improved from prior year due to higher sales margin. Bioretec listed on Nasdaq First North Growth Market Finland in September 2021.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Bioretec

When was Bioretec founded?Bioretec was founded in 2003.
Where is Bioretec headquartered?Bioretec is headquartered in Finland.
How many employees does Bioretec have?As of today, Bioretec has over 47 employees.
Is Bioretec publicly listed?Yes, Bioretec is a public company listed on Nasdaq Helsinki.
What is the stock symbol of Bioretec?Bioretec trades under BRETEC ticker.
When did Bioretec go public?Bioretec went public in 2022.
Who are competitors of Bioretec?Bioretec main competitors include aap Implantate, Acarix, BrainCool, Carclo, Vivos, Ortoma, NeuroOne Medical, CytoSorbents, Implanet, Diagnostic Medical Systems.
What is the current market cap of Bioretec?Bioretec's current market cap is $33M.
What is the current revenue of Bioretec?Bioretec's last 12 months revenue is $5M.
What is the current revenue growth of Bioretec?Bioretec revenue growth (NTM/LTM) is 51%.
What is the current EV/Revenue multiple of Bioretec?Current revenue multiple of Bioretec is 5.8x.
Is Bioretec profitable?No, Bioretec is not profitable.
What is the current EBITDA of Bioretec?Bioretec has negative EBITDA and is not profitable.
What is Bioretec's EBITDA margin?Bioretec's last 12 months EBITDA margin is (182%).
What is the current EV/EBITDA multiple of Bioretec?Current EBITDA multiple of Bioretec is (3.2x).
What is the current FCF of Bioretec?Bioretec's last 12 months FCF is ($8M).
What is Bioretec's FCF margin?Bioretec's last 12 months FCF margin is (157%).
What is the current EV/FCF multiple of Bioretec?Current FCF multiple of Bioretec is (3.7x).
How many companies Bioretec has acquired to date?Bioretec hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Bioretec has invested to date?Bioretec hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Bioretec

Lists including Bioretec

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial